References
- Directive 2001/83/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 6 November 2001 on the Community code relating to medicinal products for human use. Available from: http://ec.europa.eu/health/files/eudralex/vol-1/dir_2001_83_consol_2012/dir_2001_83_cons_2012_fr.pdf [cited 5 May 2016]..
- Regulation (EC) No 1394/2007 of the European Parliament and of the council of 13 November 2007 on advanced therapy medicinal products and amending Directive 2001/83/EC and Regulation (EC) No 726/2004. Available from: http://ec.europa.eu/health/files/eudralex/vol-1/reg_2007_1394/reg_2007_1394_en.pdf [cited 5 May 2016]..
- Hanna E, Remuzat C, Auquier P, Toumi M. Advanced therapy medicinal products: Current and future perspectives. J Mark Access Health Policy. 2016; 4 : 31036, doi: http://dx.doi.org/10.3402/jmahp.v4.31036 .
- Meldrum ML. A brief history of the randomized controlled trial. From oranges and lemons to the gold standard. Hematol Oncol Clin North Am. 2000; 14(4): 745–60. [PubMed Abstract] vii.
- Sibbald B, Roland M. Understanding controlled trials: Why are randomised controlled trials important?. BMJ. 1998; 316: 201.
- Singal AG, Higgins PDR, Waljee AK. A primer on effectiveness and efficacy trials. Clin Transl Gastroenterol. 2014; 5(1): e45. doi: http://dx.doi.org/10.1038/ctg.2013.13 .
- World Health Organization (WHO). Health promotion evaluation: Recommendations to policymakers. Report of the WHO European working group on health promotion evaluation. 1998; Copenhagen, Denmark: WHO.
- Lièvre M, Ménard J, Bruckert E, Cogneau J, Delahaye F, Giral P, etal. Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility. BMJ. 2001; 322(7286): 603–6.
- Chapman SJ, Shelton B, Mahmood H, Fitzgerald JE, Harrison EM, Bhangu A, etal. Discontinuation and non-publication of surgical randomised controlled trials. Observational study BMJ. 2014; 349: 6870.
- Lopienski K. Retention in clinical trials – Keeping patients on protocol, June 2015. Available from: http://forteresearch.com/news/infographic-retention-in-clinical-trials-keeping-patients-on-protocols/ [cited 5 May 2016]..
- Svennebring AM, Wikberg JE. Net present value approaches for drug discovery. Springer Plus. 2013; 2 140. doi: http://dx.doi.org/10.1186/2193-1801-2-140 .
- Kasenda B, von Elm E, You J, Blümle A, Tomonaga Y, Saccilotto R, etal. Prevalence, characteristics, and publication of discontinued randomized trials. JAMA. 2014; 311(10): 1045–51.
- Kaitin K, DiMasi J. Pharmaceutical innovation in the 21st Century: New drug approvals in the first decade, 2000–2009. Clin Pharmacol Ther. 2011; 89: 183–8. doi: http://dx.doi.org/10.1038/clpt.2010.286 [PubMed Abstract].
- Mullard A. New drugs cost US$2.6 billion to develop. Nat Rev Drug Discov. 2014; 13 877. doi: http://dx.doi.org/10.1038/nrd4507 .
- Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation. Transforming Clinical Research in the United States: Challenges and opportunities: Workshop summary. 2010; Washington (DC): National Academies Press (US). 3, Challenges in clinical research. Available from: http://www.ncbi.nlm.nih.gov/books/NBK50888/ [cited 5 May 2016]..
- Stensland KD, Latif A, Hendricks R, Roper N, McBride R, Hall SJ, etal. Prevalence and characteristics of prematurely terminated cancer clinical trials, 2013 ASCO Annual Meeting, 31 May 2013. Available from: http://hwmaint.meeting.ascopubs.org/cgi/content/abstract/31/15_suppl/6613 [cited 5 May 2016]..
- Bernardez-Pereira S, Lopes RD, Carrion MJ, Santucci EV, Soares RM, de Oliveira AM, etal. Prevalence, characteristics, and predictors of early termination of cardiovascular clinical trials due to low recruitment: Insights from the ClinicalTrials.gov registry. Am Heart J. 2014; 168(2): 213–9.
- La Croix: Les médicaments du cancer atteignent un niveau de prix immoral. Entretien avec Jean-Paul Vernant. Available from: http://www.la-croix.com/Actualite/France/Les-medicaments-du-cancer-atteignent-un-niveau-de-prix-immoral-2013-11-06-1056577 (2013) [cited 1 April 2016]..
- Kantarjian H, Steensma D, Rius SJ, Elshaug A, Light D. High cancer drug prices in the United States: Reasons and proposed solutions. J Oncol Pract. 2014; 10: e208–11.
- Pfister DG. The just price of cancer drugs and the growing cost of cancer care: Oncologists need to be part of the solution. J Clin Oncol. 2013; 31: 3487–9.